All Inventions from NCI

  • High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
    •
       Ref: E-198-2018 | Updated: Oct 15, 2018 | NCI
  • New Insect Sf9-ET Cell Line for Determining Baculovirus Titers
    •
       Ref: E-009-2008 | Updated: Oct 15, 2018 | NCI
  • Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)
    •
       Ref: E-094-2018 | Updated: Oct 15, 2018 | NCI
  • Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1
    •    Ref: E-069-2016 | Updated: Oct 15, 2018 | NCI
  • Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine
    •
       Ref: E-169-2016 | Updated: Oct 12, 2018 | NCI
  • Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
    •
       Ref: E-229-2017 | Updated: Oct 12, 2018 | NCI
  • Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed...
    •
       Ref: E-138-2006 | Updated: Oct 12, 2018 | NCI
  • Methods For Treating or Preventing Inflammation and Periodontitis
    •
       Ref: E-015-2018 | Updated: Oct 12, 2018 | NCI
  • T cell Receptors Which Recognize Mutated EGFR
    •
       Ref: E-098-2018 | Updated: Oct 12, 2018 | NCI
  • Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
    •
       Ref: E-068-2018 | Updated: Oct 12, 2018 | NCI
  • The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof
    •
       Ref: E-244-2004 | Updated: Oct 12, 2018 | NCI
  • Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus
    •    Ref: E-287-2012 | Updated: Oct 1, 2018 | NCI
  • Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy
    •
       Ref: E-065-2017 | Updated: Sep 5, 2018 | NCI
  • A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer...
    •
       Ref: E-280-2016 | Updated: Aug 15, 2018 | NCI
  • A Triple Combination HIV Microbicide
    •    Ref: E-137-2016 | Updated: Aug 14, 2018 | NCI
  • Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation
    •
       Ref: E-069-2018 | Updated: Aug 14, 2018 | NCI
  • Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens
    •
       Ref: E-052-2013 | Updated: Aug 3, 2018 | NCI
  • New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies
    •    Ref: E-016-2018 | Updated: Aug 3, 2018 | NCI, CCR, LMB
  • Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination
    •
       Ref: E-157-2000 | Updated: Aug 1, 2018 | NCI
  • Improved HIV Vaccines Through Ras Activation
    •
       Ref: E-062-2014 | Updated: Aug 1, 2018 | NCI
  • Renal Selective Unsaturated Englerin Analogues
    •
       Ref: E-072-2014 | Updated: Aug 1, 2018 | NCI
  • Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range
    •
       Ref: E-143-2017 | Updated: Jul 27, 2018 | NCI
  • Fusion Proteins as HIV-1 Entry Inhibitors
    •
       Ref: E-086-2015 | Updated: Jul 27, 2018 | NCI
  • Scytovirin Domain 1 Related Polypeptides
    •    Ref: E-180-2005 | Updated: Jul 27, 2018 | NCI
  • Targeted RNA/DNA Nanoparticles with Single Stranded RNA Toeholds
    •
       Ref: E-078-2016 | Updated: Jul 27, 2018 | NCI
  • A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18
    •
       Ref: E-137-2004 | Updated: Jul 19, 2018 | NCI
  • Gene Signature for Predicting Solid Tumors Patient Prognosis
    •
       Ref: E-024-2009 | Updated: Jul 19, 2018 | NCI
  • Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma
    •
       Ref: E-291-2015 | Updated: Jul 19, 2018 | NCI
  • Genomics-based Diagnostic Assay for Cancer
    •
       Ref: E-023-2009 | Updated: Jul 19, 2018 | NCI
  • Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics
    •
       Ref: E-019-2014 | Updated: Jul 19, 2018 | NCI
  • Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue
    •
       Ref: E-139-2015 | Updated: Jul 19, 2018 | NCI
  • Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen
    •
       Ref: E-021-2015 | Updated: Jul 19, 2018 | NCI
  • Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic
    •
       Ref: E-133-2009 | Updated: Jul 19, 2018 | NCI
  • Video Monitoring and Analysis System for Vivarium Cage Racks
    •
       Ref: E-090-2013 | Updated: Jul 19, 2018 | NCI
  • Zirconium-89 PET Imaging Agent for Cancer
    •
       Ref: E-111-2013 | Updated: Jul 19, 2018 | NCI
  • Niclosamide for Treating Adrenocortical Cancer (ACC)
    •
       Ref: E-089-2016 | Updated: Jul 16, 2018 | NCI
  • Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen...
    •
       Ref: E-107-2017 | Updated: Jul 13, 2018 | NCI
  • Polypeptides for Stimulation of Immune Response (Adjuvants)
    •
       Ref: E-185-2008 | Updated: Jul 13, 2018 | NCI
  • Modified POTE Peptides for Cancer Immunotherapy
    •
       Ref: E-003-2010 | Updated: Jun 19, 2018 | NCI
  • Immunocompetent Mouse Model for Tracking Cancer Progression
    •
       Ref: E-173-2010 | Updated: Jun 18, 2018 | NCI
  • Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics
    •
       Ref: E-765-2013 | Updated: Jun 18, 2018 | NCI
  • Nanoparticles for the targeted treatment of infected cells
    •
       Ref: E-039-2012 | Updated: Jun 8, 2018 | NCI
  • Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer
    •
       Ref: E-236-2012 | Updated: Jun 7, 2018 | NCI
  • Assay to Screen Anti-metastatic Drugs
    •
       Ref: E-088-2013 | Updated: Jun 7, 2018 | NCI
  • Co-Transcriptional Assembly of Modified RNA Nanoparticles
    •
       Ref: E-223-2012 | Updated: Jun 7, 2018 | NCI
  • Mouse Model for the Preclinical Study of Metastatic Disease
    •
       Ref: E-296-2012 | Updated: Jun 7, 2018 | NCI
  • Software for Modeling Delivery and Penetration of Antibody Conjugates
    •
       Ref: E-060-2012 | Updated: Jun 7, 2018 | NCI
  • A549 Cells: Lung Carcinoma Cell Line for Adenovirus
    •
       Ref: E-129-2009 | Updated: May 30, 2018 | NCI
  • BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
    •
       Ref: E-009-2010 | Updated: May 30, 2018 | NCI
  • Dual-Function Protein ATIA for Diagnostics and Therapeutics of Glioblastoma
    •    Ref: E-178-2009 | Updated: May 30, 2018 | NCI
  • High-throughput Assay to Identify New Cancer Drugs
    •
       Ref: E-031-2013 | Updated: May 30, 2018 | NCI
  • HIV-1 Therapeutic Inhibits Viral Entry
    •
       Ref: E-033-2013 | Updated: May 30, 2018 | NCI
  • Human Antibodies Against Middle East Respiratory Syndrome Coronavirus
    •
       Ref: E-002-2014 | Updated: May 30, 2018 | NCI
  • MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors
    •
       Ref: E-001-2012 | Updated: May 30, 2018 | NCI
  • Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer
    •
       Ref: E-226-2014 | Updated: May 16, 2018 | NCI
  • Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor...
    •
       Ref: E-068-2011 | Updated: May 4, 2018 | NCI
  • Human T Cell Receptors for Treating Cancer
    •
       Ref: E-269-2010 | Updated: May 4, 2018 | NCI
  • High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
    •
       Ref: E-136-2012 | Updated: Apr 24, 2018 | NCI
  • Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer
    •
       Ref: E-025-2010 | Updated: Apr 24, 2018 | NCI
  • Knockout and Conditional Knockout Mice-GPR116
    •    Ref: E-269-2012 | Updated: Apr 23, 2018 | NCI
  • Anti-Viral Compounds that Inhibit HIV Activity
    •
       Ref: E-081-2011 | Updated: Apr 20, 2018 | NCI
  • Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C
    •    Ref: E-217-2011 | Updated: Apr 20, 2018 | NCI
  • Method and Device for Selectively Labeling RNA
    •
       Ref: E-119-2013 | Updated: Apr 18, 2018 | NCI
  • Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain
    •
       Ref: E-094-2013 | Updated: Apr 18, 2018 | NCI
  • Software for Accurate Segmentation of Cell Nuclei in Breast Tissue
    •
       Ref: E-106-2010 | Updated: Apr 18, 2018 | NCI
  • B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia
    •
       Ref: E-163-2009 | Updated: Apr 17, 2018 | NCI
  • Method for Generating Pluripotent and Multipotent Cells
    •
       Ref: E-086-2012 | Updated: Apr 17, 2018 | NCI
  • Vaccines for HIV
    •
       Ref: E-087-2015 | Updated: Apr 17, 2018 | NCI
  • Prognostic Biomarkers for Patients with Early Stage Lung Cancer
    •    Ref: E-048-2012 | Updated: Apr 9, 2018 | NCI
  • Combination Cancer Therapy with HDAC Inhibitors
    •
       Ref: E-065-2016 | Updated: Apr 3, 2018 | NCI
  • Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex
    •
       Ref: E-053-2015 | Updated: Apr 3, 2018 | NCI
  • Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
    •
       Ref: E-034-2013 | Updated: Mar 29, 2018 | NCI
  • Nitroxyl (HNO) Releasing Therapeutics
    •
       Ref: E-019-2010 | Updated: Mar 29, 2018 | NCI
  • Ratio Based Biomarkers for the Prediction of Cancer Survival
    •
       Ref: E-025-2009 | Updated: Mar 29, 2018 | NCI
  • Mouse Xenograft Model for Mesothelioma
    •
       Ref: E-302-2009 | Updated: Mar 27, 2018 | NCI
  • Cancer Immunotherapy Using Virus-like Particles
    •
       Ref: E-050-2014 | Updated: Mar 26, 2018 | NCI
  • Novel Anti-HIV Proteins from Coral Reefs
    •
       Ref: E-295-2012 | Updated: Mar 26, 2018 | NCI
  • Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers
    •
       Ref: E-001-2016 | Updated: Mar 23, 2018 | NCI
  • Device to guide oxygen over cells for photo-oxidation
    •
       Ref: E-244-2016 | Updated: Mar 21, 2018 | NCI
  • A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof
    •
       Ref: E-271-2014 | Updated: Mar 20, 2018 | NCI
  • Brachyury-directed Vaccine for the Prevention or Treatment of Cancers
    •
       Ref: E-055-2011 | Updated: Mar 20, 2018 | NCI
  • Schweinfurthins and Uses Thereof
    •
       Ref: E-183-2009 | Updated: Mar 20, 2018 | NCI
  • Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)
    •
       Ref: E-183-2017 | Updated: Mar 13, 2018 | NCI
  • Improved Personalized Cancer Immunotherapy
    •
       Ref: E-059-2013 | Updated: Mar 9, 2018 | NCI
  • New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
    •    Ref: E-089-2010 | Updated: Mar 9, 2018 | NCI
  • NSAIDs that Assist the Treatment of Human Diseases
    •
       Ref: E-131-2011 | Updated: Feb 21, 2018 | NCI
  • A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis
    •
       Ref: E-058-2009 | Updated: Feb 16, 2018 | NCI
  • Cancer-reactive T cells from Peripheral Blood
    •
       Ref: E-149-2015 | Updated: Feb 16, 2018 | NCI
  • Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)
    •
       Ref: E-181-2009 | Updated: Feb 16, 2018 | NCI
  • Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)
    •
       Ref: E-158-2010 | Updated: Feb 5, 2018 | NCI
  • IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
    •
       Ref: E-247-2015 | Updated: Jan 17, 2018 | NCI
  • Device for Growing Mammalian Cells on EM Grids
    •
       Ref: E-243-2016 | Updated: Dec 20, 2017 | NCI
  • Natural product-based anti-cancer agents: aza-Englerin analogues
    •
       Ref: E-090-2014 | Updated: Dec 20, 2017 | NCI
  • Methods of analyzing virus-derived therapeutics
    •
       Ref: E-240-2015 | Updated: Dec 19, 2017 | NCI
  • Processes for Producing and Purifying Nucleic Acid-Containing Compositions
    •
       Ref: E-267-2014 | Updated: Dec 17, 2017 | NCI
  • Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations
    •
       Ref: E-028-2015 | Updated: Dec 7, 2017 | NCI
  • Methods of Producing Effective T-cell Populations Using Akt Inhibitors
    •
       Ref: E-013-2016 | Updated: Dec 5, 2017 | NCI
  • Metastatic ovarian cancer mouse models and cell lines for preclinical studies
    •
       Ref: E-069-2012 | Updated: Nov 20, 2017 | NCI
  • Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics
    •
       Ref: E-351-2013 | Updated: Nov 14, 2017 | NCI
  • Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia
    •
       Ref: E-014-2017 | Updated: Oct 27, 2017 | NCI

    Pages


    Displaying 101 - 200 of 241

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057